COMPASS® AND CHART®
Genoptix’s flagship service is COMPASS, a comprehensive diagnostic approach for hematomalignancies. Integrating morphology, flow cytometry, cytogenetics, FISH, and molecular testing as medically appropriate, COMPASS provides definite results via a streamlined report and actionable diagnosis. CHART maps multiple COMPASS workups and intervening clinical actions to measure disease progression and response to treatment over time as well as monitoring and measurement of MRD. By delivering definite answers, COMPASS and CHART save precious time and help to improve patients’ outcomes.
Genoptix provides molecular profiles for myeloid malignancies, myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML) in heme, as well as melanoma for skin cancer. By improving risk stratification above and beyond today’s standard models, we ensure that clinicians can provide the most appropriate management for their patients.